Therefore, we hypothesized that enzalutamide, combined with fulvestrant, would be effective in patients with ER+ AR+ metastatic BC resistant to traditional therapeutic strategies targeting ER or estrogen production (AI therapy). Here, AR is linked to breast cancer.